These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 37865999)
1. Co-expression of IL-4/IL-15-based inverted cytokine receptor in CAR-T cells overcomes IL-4 signaling in immunosuppressive pancreatic tumor microenvironment. Zhou Y; Farooq MA; Ajmal I; He C; Gao Y; Guo D; Duan Y; Jiang W Biomed Pharmacother; 2023 Dec; 168():115740. PubMed ID: 37865999 [TBL] [Abstract][Full Text] [Related]
2. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors. Parihar R; Rivas C; Huynh M; Omer B; Lapteva N; Metelitsa LS; Gottschalk SM; Rooney CM Cancer Immunol Res; 2019 Mar; 7(3):363-375. PubMed ID: 30651290 [TBL] [Abstract][Full Text] [Related]
3. Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer. Mohammed S; Sukumaran S; Bajgain P; Watanabe N; Heslop HE; Rooney CM; Brenner MK; Fisher WE; Leen AM; Vera JF Mol Ther; 2017 Jan; 25(1):249-258. PubMed ID: 28129119 [TBL] [Abstract][Full Text] [Related]
4. An IL-4/21 Inverted Cytokine Receptor Improving CAR-T Cell Potency in Immunosuppressive Solid-Tumor Microenvironment. Wang Y; Jiang H; Luo H; Sun Y; Shi B; Sun R; Li Z Front Immunol; 2019; 10():1691. PubMed ID: 31379876 [TBL] [Abstract][Full Text] [Related]
5. Combination therapy of DKK1 inhibition and NKG2D chimeric antigen receptor T cells for the treatment of gastric cancer. Zhang Y; Liang K; Zhou X; Zhang X; Xu H; Dai H; Song X; Yang X; Liu B; Shi T; Wei J Cancer Sci; 2023 Jul; 114(7):2798-2809. PubMed ID: 37151176 [TBL] [Abstract][Full Text] [Related]
6. T Cells Expressing NKG2D CAR with a DAP12 Signaling Domain Stimulate Lower Cytokine Production While Effective in Tumor Eradication. Ng YY; Tay JCK; Li Z; Wang J; Zhu J; Wang S Mol Ther; 2021 Jan; 29(1):75-85. PubMed ID: 32956627 [TBL] [Abstract][Full Text] [Related]
7. Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy. Murad JM; Baumeister SH; Werner L; Daley H; Trébéden-Negre H; Reder J; Sentman CL; Gilham D; Lehmann F; Snykers S; Sentman ML; Wade T; Schmucker A; Fanger MW; Dranoff G; Ritz J; Nikiforow S Cytotherapy; 2018 Jul; 20(7):952-963. PubMed ID: 30180944 [TBL] [Abstract][Full Text] [Related]
8. Eradication of Hepatocellular Carcinoma by NKG2D-Based CAR-T Cells. Sun B; Yang D; Dai H; Liu X; Jia R; Cui X; Li W; Cai C; Xu J; Zhao X Cancer Immunol Res; 2019 Nov; 7(11):1813-1823. PubMed ID: 31484657 [TBL] [Abstract][Full Text] [Related]
9. Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells. Han Y; Xie W; Song DG; Powell DJ J Hematol Oncol; 2018 Jul; 11(1):92. PubMed ID: 29980239 [TBL] [Abstract][Full Text] [Related]
10. Arming cytotoxic lymphocytes for cancer immunotherapy by means of the NKG2D/NKG2D-ligand system. Lazarova M; Wels WS; Steinle A Expert Opin Biol Ther; 2020 Dec; 20(12):1491-1501. PubMed ID: 32726145 [TBL] [Abstract][Full Text] [Related]
11. [Construction of NKG2D CAR-NK92 cells and its killing effect on multiple myeloma cells]. Long J; Zheng R; Ye S; Ke S; Duan D; Wei C; Gao J Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2023 Jul; 39(7):577-585. PubMed ID: 37403715 [TBL] [Abstract][Full Text] [Related]
12. Development of NKG2D-based chimeric antigen receptor-T cells for gastric cancer treatment. Tao K; He M; Tao F; Xu G; Ye M; Zheng Y; Li Y Cancer Chemother Pharmacol; 2018 Nov; 82(5):815-827. PubMed ID: 30132099 [TBL] [Abstract][Full Text] [Related]
13. Multifunctional mRNA-Based CAR T Cells Display Promising Antitumor Activity Against Glioblastoma. Meister H; Look T; Roth P; Pascolo S; Sahin U; Lee S; Hale BD; Snijder B; Regli L; Ravi VM; Heiland DH; Sentman CL; Weller M; Weiss T Clin Cancer Res; 2022 Nov; 28(21):4747-4756. PubMed ID: 36037304 [TBL] [Abstract][Full Text] [Related]
14. T cells expressing NKG2D chimeric antigen receptors efficiently eliminate glioblastoma and cancer stem cells. Yang D; Sun B; Dai H; Li W; Shi L; Zhang P; Li S; Zhao X J Immunother Cancer; 2019 Jul; 7(1):171. PubMed ID: 31288857 [TBL] [Abstract][Full Text] [Related]
15. Orthotopic and Heterotopic Murine Models of Pancreatic Cancer Exhibit Different Immunological Microenvironments and Different Responses to Immunotherapy. Wang J; Liu X; Ji J; Luo J; Zhao Y; Zhou X; Zheng J; Guo M; Liu Y Front Immunol; 2022; 13():863346. PubMed ID: 35874730 [TBL] [Abstract][Full Text] [Related]
16. Augmented anti-tumor activity of NK-92 cells expressing chimeric receptors of TGF-βR II and NKG2D. Wang Z; Guo L; Song Y; Zhang Y; Lin D; Hu B; Mei Y; Sandikin D; Liu H Cancer Immunol Immunother; 2017 Apr; 66(4):537-548. PubMed ID: 28184969 [TBL] [Abstract][Full Text] [Related]